Proton Pump Inhibitor Therapy Increases the Risk of Spontaneous Bacterial Peritonitis in Patients with HBV-Related Acute-on-Chronic Liver Failure.
Acute-on-chronic liver failure
MELD score
Proton pump inhibitor
Spontaneous bacterial peritonitis
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
29
04
2021
accepted:
24
06
2021
pubmed:
27
7
2021
medline:
16
9
2021
entrez:
26
7
2021
Statut:
ppublish
Résumé
Spontaneous bacterial peritonitis (SBP) is a common infection in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF). SBP significantly increases the mortality rate and medical costs. The association between proton pump inhibitor (PPI) use and SBP remains unclear. We conducted a retrospective study to investigate the association between PPI use and SBP in patients with HBV-related ACLF and to explore the risk factors for SBP. We compared the SBP incidence between the PPI and non-PPI groups before and after propensity score matching and explored the association between the duration and type of PPI and SBP occurrence. Risk factors for SBP occurrence were determined by univariate and multivariate logistic regression analysis. The SBP incidence was higher in the PPI group than in the non-PPI group before and after propensity score matching. The SBP incidence increased for elevated MELD scores in PPI users. There was a similar SBP incidence in both different types and durations of PPI users. MELD score, old age, male sex, and high WBC count were significant independent risk factors for SBP in PPI users with HBV-related ACLF in the hospital. PPI therapy increases the risk of SBP development in patients with HBV-related ACLF. MELD score, old age, male sex, and high WBC count could serve as predictors of SBP in PPI users. Caution should be taken regarding PPI use, especially for patients with MELD scores > 30.
Identifiants
pubmed: 34308513
doi: 10.1007/s12325-021-01844-1
pii: 10.1007/s12325-021-01844-1
doi:
Substances chimiques
Proton Pump Inhibitors
0
Types de publication
Journal Article
Langues
eng
Pagination
4675-4694Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.
Références
Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update [published correction appears in Hepatol Int. 2019 Nov, 13(6), pp. 826–828]. Hepatol Int. 2019;13:353–90.
pubmed: 31172417
doi: 10.1007/s12072-019-09946-3
pmcid: 31172417
Shalimar, Rout G, Jadaun SS, et al. Prevalence, predictors and impact of bacterial infection in acute on chronic liver failure patients. Dig Liver Dis. 2018; 50: 1225–1231.
Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144:1426-1437.e14379.
pubmed: 23474284
doi: 10.1053/j.gastro.2013.02.042
pmcid: 23474284
Qin G, Shao JG, Zhu YC, et al. Population-representative incidence of acute-on-chronic liver failure: a prospective cross-sectional study. J Clin Gastroenterol. 2016;50:670–5.
pubmed: 27136963
pmcid: 4978606
doi: 10.1097/MCG.0000000000000538
Abbas Z, Shazi L. Pattern and profile of chronic liver disease in acute on chronic liver failure. Hepatol Int. 2015;9:366–72.
pubmed: 26016461
doi: 10.1007/s12072-015-9627-z
pmcid: 26016461
Yuan L, Zeng BM, Liu LL, et al. Risk factors for progression to acute-on-chronic liver failure during severe acute exacerbation of chronic hepatitis B virus infection. World J Gastroenterol. 2019;25:2327–37.
pubmed: 31148904
pmcid: 6529889
doi: 10.3748/wjg.v25.i19.2327
Fernández J, Prado V, Trebicka J, et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J Hepatol. 2019;70:398–411.
pubmed: 30391380
doi: 10.1016/j.jhep.2018.10.027
pmcid: 30391380
Olson JC. Acute-on-chronic and decompensated chronic liver failure: definitions, epidemiology, and prognostication. Crit Care Clin. 2016;32:301–9.
pubmed: 27339672
doi: 10.1016/j.ccc.2016.02.001
pmcid: 27339672
Sundaram V, Jalan R, Wu T, et al. Factors associated with survival of patients with severe acute-on-chronic liver failure before and after liver transplantation. Gastroenterology. 2019; 156: 1381–1391. e3.
Zhang Y, Nie Y, Liu L, Zhu X. Assessing the prognostic scores for the prediction of the mortality of patients with acute-on-chronic liver failure: a retrospective study. PeerJ. 2020; 8: e9857.
Chen T, Yang Z, Choudhury AK, et al. Complications constitute a major risk factor for mortality in hepatitis B virus-related acute-on-chronic liver failure patients: a multi-national study from the Asia-Pacific region. Hepatol Int. 2019;13:695–705.
pubmed: 31650510
doi: 10.1007/s12072-019-09992-x
pmcid: 31650510
Zhai XR, Tong JJ, Wang HM, et al. Infection deteriorating hepatitis B virus related acute-on-chronic liver failure: a retrospective cohort study. BMC Gastroenterol. 2020;20:320.
pubmed: 32993547
pmcid: 7526233
doi: 10.1186/s12876-020-01473-y
Fernández J, Acevedo J, Wiest R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut. 2018;67:1870–80.
pubmed: 28847867
doi: 10.1136/gutjnl-2017-314240
pmcid: 28847867
Dever JB, Sheikh MY. Review article: spontaneous bacterial peritonitis–bacteriology, diagnosis, treatment, risk factors and prevention. Aliment Pharmacol Ther. 2015;41:1116–31.
pubmed: 25819304
doi: 10.1111/apt.13172
pmcid: 25819304
Engelmann C, Berg T. Management of infectious complications associated with acute-on-chronic liver failure. Visc Med. 2018;34:261–8.
pubmed: 30345283
pmcid: 6189542
doi: 10.1159/000491107
Schwabl P, Bucsics T, Soucek K, et al. Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. Liver Int. 2015;35:2121–8.
pubmed: 25644943
doi: 10.1111/liv.12795
pmcid: 25644943
Min YW, Lim KS, Min BH, et al. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. Aliment Pharmacol Ther. 2014;40:695–704.
pubmed: 25078671
doi: 10.1111/apt.12875
pmcid: 25078671
Choi EJ, Lee HJ, Kim KO, et al. Association between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Scand J Gastroenterol. 2011;46:616–20.
pubmed: 21275825
doi: 10.3109/00365521.2011.551891
pmcid: 21275825
Bajaj JS, Zadvornova Y, Heuman DM, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol. 2009;104:1130–4.
pubmed: 19337238
doi: 10.1038/ajg.2009.80
pmcid: 19337238
Terg R, Casciato P, Garbe C, et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study. J Hepatol. 2015;62:1056–60.
pubmed: 25481567
doi: 10.1016/j.jhep.2014.11.036
pmcid: 25481567
Goel GA, Deshpande A, Lopez R, Hall GS, van Duin D, Carey WD. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol. 2012;10:422–7.
pubmed: 22155557
doi: 10.1016/j.cgh.2011.11.019
pmcid: 22155557
Dam G, Vilstrup H, Watson H, Jepsen P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology. 2016;64:1265–72.
pubmed: 27474889
doi: 10.1002/hep.28737
pmcid: 27474889
Mandorfer M, Bota S, Schwabl P, et al. Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites. PLoS One. 2014; 9: e110503.
Pang SH, Graham DY. A clinical guide to using intravenous proton-pump inhibitors in reflux and peptic ulcers. Therap Adv Gastroenterol. 2010;3(1):11–22.
pubmed: 21180586
pmcid: 3002568
doi: 10.1177/1756283X09352095
Corleto VD, Festa S, Di Giulio E, Annibale B. Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes. 2014;21:3–8.
pubmed: 24310148
doi: 10.1097/MED.0000000000000031
pmcid: 24310148
Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis—a practical guide. Aliment Pharmacol Ther. 2013;37:1132–56.
pubmed: 23638982
doi: 10.1111/apt.12324
pmcid: 23638982
O’Leary JG, Bajaj JS, Tandon P, et al. Outcomes after listing for liver transplant in patients with acute-on-chronic liver failure: the multicenter North American consortium for the study of end-stage liver disease experience. Liver Transpl. 2019;25:571–9.
pubmed: 30724010
doi: 10.1002/lt.25426
pmcid: 30724010
European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397–417.
doi: 10.1016/j.jhep.2010.05.004
Nakayama N, Uemura H, Uchida Y, et al. A multicenter pilot survey to clarify the clinical features of patients with acute-on-chronic liver failure in Japan. Hepatol Res. 2018;48:303–12.
pubmed: 29341357
doi: 10.1111/hepr.13064
pmcid: 29341357
Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure [published correction appears in Hepatology. 2011 Sep 2;54(3):1114]. Hepatology. 2011;53(3):774–780.
Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98.
pubmed: 26563120
doi: 10.1007/s12072-015-9675-4
pmcid: 26563120
Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. BMJ. 2020;370:m2200.
Shi Y, Yang Y, Hu Y, et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology. 2015;62(1):232–42.
doi: 10.1002/hep.27795
pubmed: 25800029
pmcid: 25800029
Kabbani AR, Schultalbers M, Tergast T, et al. Influence of a spontaneous bacterial peritonitis, nosocomial infections and acute-on-chronic liver failure on treatment revenues in patients with decompensated cirrhosis in Germany. Z Gastroenterol. 2020;58:855–67.
pubmed: 32947631
doi: 10.1055/a-1217-7549
pmcid: 32947631
Allen AM, Kim WR, Moriarty JP, Shah ND, Larson JJ, Kamath PS. Time trends in the health care burden and mortality of acute on chronic liver failure in the United States. Hepatology. 2016;64:2165–72.
pubmed: 27696493
doi: 10.1002/hep.28812
pmcid: 27696493
Janka T, Tornai T, Borbély B, et al. Deleterious effect of proton pump inhibitors on the disease course of cirrhosis. Eur J Gastroenterol Hepatol. 2020;32:257–64.
pubmed: 31464790
doi: 10.1097/MEG.0000000000001499
pmcid: 31464790
Kwon JH, Koh SJ, Kim W, et al. Mortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitis. J Gastroenterol Hepatol. 2014;29:775–81.
pubmed: 24219827
doi: 10.1111/jgh.12426
pmcid: 24219827
Deshpande A, Pasupuleti V, Thota P, et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol. 2013;28:235–42.
pubmed: 23190338
doi: 10.1111/jgh.12065
pmcid: 23190338
Trikudanathan G, Israel J, Cappa J, O’Sullivan DM. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients - a systematic review and meta-analysis. Int J Clin Pract. 2011;65:674–8.
pubmed: 21564440
doi: 10.1111/j.1742-1241.2011.02650.x
pmcid: 21564440
O’Leary JG, Reddy KR, Wong F, et al. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13:753-9.e92.
pubmed: 25130937
doi: 10.1016/j.cgh.2014.07.060
pmcid: 25130937
Campbell MS, Obstein K, Reddy KR, Yang YX. Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci. 2008;53:394–8.
pubmed: 17616817
doi: 10.1007/s10620-007-9899-9
pmcid: 17616817
Kim JH, Lim KS, Min YW, et al. Proton pump inhibitors do not increase the risk for recurrent spontaneous bacterial peritonitis in patients with cirrhosis. J Gastroenterol Hepatol. 2017;32:1064–70.
pubmed: 28449345
doi: 10.1111/jgh.13637
pmcid: 28449345
de Vos M, De Vroey B, Garcia BG, et al. Role of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Liver Int. 2013;33:1316–23.
pubmed: 23730823
doi: 10.1111/liv.12210
pmcid: 23730823
Hung TH, Tseng CW, Lee HF, Tsai CC, Tsai CC. Effect of proton pump inhibitors on mortality in patients with cirrhosis and spontaneous bacterial peritonitis. Ann Hepatol. 2018;17:933–9.
pubmed: 30600287
doi: 10.5604/01.3001.0012.7193
pmcid: 30600287
Chang SS, Lai CC, Lee MG, et al. Risk of spontaneous bacterial peritonitis associated with gastric Acid suppression. Medicine (Baltimore). 2015; 94: e944.
Huang KW, Kuan YC, Luo JC, Lin CL, Liang JA, Kao CH. Impact of long-term gastric acid suppression on spontaneous bacterial peritonitis in patients with advanced decompensated liver cirrhosis. Eur J Intern Med. 2016;32:91–5.
pubmed: 27139916
doi: 10.1016/j.ejim.2016.04.016
pmcid: 27139916
Lutz P, Goeser F, Kaczmarek DJ, et al. Relative ascites polymorphonuclear cell count indicates bacterascites and risk of spontaneous bacterial peritonitis. Dig Dis Sci. 2017;62:2558–68.
pubmed: 28597106
doi: 10.1007/s10620-017-4637-4
pmcid: 28597106
Bajaj JS, O’Leary JG, Reddy KR, et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology. 2012;56(6):2328–35.
pubmed: 22806618
doi: 10.1002/hep.25947
pmcid: 22806618
Obstein KL, Campbell MS, Reddy KR, Yang YX. Association between model for end-stage liver disease and spontaneous bacterial peritonitis. Am J Gastroenterol. 2007;102:2732–6.
pubmed: 17714556
doi: 10.1111/j.1572-0241.2007.01485.x
pmcid: 17714556
Yip TC, Chan HL, Tse YK, et al. On-treatment improvement of MELD score reduces death and hepatic events in patients with hepatitis B-related cirrhosis. Am J Gastroenterol. 2018;113:1629–38.
pubmed: 30315283
doi: 10.1038/s41395-018-0247-9
pmcid: 30315283
Kraja B, Sina M, Mone I, et al. Predictive Value of the Model of End-Stage Liver Disease in Cirrhotic Patients with and without Spontaneous Bacterial Peritonitis. Gastroenterol Res Pract. 2012; 2012: 539059.
Wang X, Wang BM, Jiang K, et al. The predictive value of end-stage liver disease model for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Zhonghua Nei Ke Za Zhi. 2009;48:629–32.
pubmed: 19954052
pmcid: 19954052
Khan R, Ravi S, Chirapongsathorn S, et al. Model for end-stage liver disease score predicts development of first episode of spontaneous bacterial peritonitis in patients with cirrhosis. Mayo Clin Proc. 2019;94:1799–806.
pubmed: 31400909
doi: 10.1016/j.mayocp.2019.02.027
pmcid: 31400909
De Roza MA, Kai L, Kam JW, et al. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol. 2019;25:4933–44.
pubmed: 31543684
pmcid: 6737311
doi: 10.3748/wjg.v25.i33.4933
Yamamoto K, Ishigami M, Honda T, et al. Influence of proton pump inhibitors on microbiota in chronic liver disease patients. Hepatol Int. 2019;13:234–44.
pubmed: 30737678
doi: 10.1007/s12072-019-09932-9
pmcid: 30737678
Bajaj JS, Acharya C, Fagan A, et al. Proton pump inhibitor initiation and withdrawal affects gut microbiota and readmission risk in cirrhosis. Am J Gastroenterol. 2018;113:1177–86.
pubmed: 29872220
doi: 10.1038/s41395-018-0085-9
pmcid: 29872220
Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569–73.
pubmed: 23828891
doi: 10.1126/science.1241165
pmcid: 23828891
Geddes K, Rubino SJ, Magalhaes JG, et al. Identification of an innate T helper type 17 response to intestinal bacterial pathogens. Nat Med. 2011;17:837–44.
pubmed: 21666695
doi: 10.1038/nm.2391
pmcid: 21666695